US EditionPublished • loading... • Updated
Novo regained weight loss footing in the pill arena — but Lilly is coming
Novo Nordisk leads the oral GLP-1 market with over 600,000 Wegovy prescriptions in two months while facing pricing pressure and new competition from Eli Lilly.
Summary by PharmaVOICE
2 Articles
2 Articles
Is Eli Lilly's Weight Loss Empire in Trouble?
Key PointsSeveral pharmaceutical companies have recently posted encouraging clinical data for their weight-loss candidates.However, most of these won't be approved soon, and Eli Lilly has strong programs of its own anyway. There are also other reasons to invest in Eli Lilly. 10 stocks we like better than Eli Lilly › Over the past two years, Eli Lilly (NYSE: LLY) has established itself as the leader in the weight loss market. That's thanks to the…
·Alexandria, United States
Read Full Article
Coverage Details
Total News Sources2
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
